Lineage Cell Therapeutics, Inc. (LCTX)
0.82
-0.02
(-2.21%)
USD |
NYAM |
Nov 19, 16:00
0.8201
0.00 (0.00%)
Pre-Market: 09:27
Lineage Cell Therapeutics Cash from Operations (Quarterly) : -5.62M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -5.62M |
| June 30, 2026 | -7.244M |
| March 31, 2026 | -8.078M |
| December 31, 2025 | -4.878M |
| September 30, 2025 | -3.616M |
| June 30, 2025 | -5.539M |
| March 31, 2025 | -4.886M |
| December 31, 2024 | -6.346M |
| September 30, 2024 | -5.787M |
| June 30, 2024 | -5.176M |
| March 31, 2024 | -5.783M |
| December 31, 2023 | -6.019M |
| September 30, 2023 | -5.037M |
| June 30, 2023 | -6.268M |
| March 31, 2023 | -11.24M |
| December 31, 2022 | -8.303M |
| September 30, 2022 | -5.48M |
| June 30, 2022 | -7.062M |
| March 31, 2022 | 21.90M |
| December 31, 2021 | -5.873M |
| September 30, 2021 | -4.848M |
| June 30, 2021 | -5.416M |
| March 31, 2021 | -7.424M |
| December 31, 2020 | -5.641M |
| September 30, 2020 | -4.847M |
| Date | Value |
|---|---|
| June 30, 2020 | -4.239M |
| March 31, 2020 | -5.026M |
| December 31, 2019 | -5.523M |
| September 30, 2019 | -7.443M |
| June 30, 2019 | -9.667M |
| March 31, 2019 | -9.314M |
| December 31, 2018 | -5.812M |
| September 30, 2018 | -7.332M |
| June 30, 2018 | -7.40M |
| March 31, 2018 | -10.34M |
| December 31, 2017 | -5.675M |
| September 30, 2017 | -7.681M |
| June 30, 2017 | -9.063M |
| March 31, 2017 | -8.098M |
| December 31, 2016 | -8.852M |
| September 30, 2016 | -8.915M |
| June 30, 2016 | -10.25M |
| March 31, 2016 | -14.31M |
| December 31, 2015 | -13.95M |
| September 30, 2015 | -11.56M |
| June 30, 2015 | -9.967M |
| March 31, 2015 | -9.069M |
| December 31, 2014 | -9.110M |
| September 30, 2014 | -8.609M |
| June 30, 2014 | -10.78M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Curis, Inc. | -5.749M |
| Armata Pharmaceuticals, Inc. | -5.516M |
| Voyager Therapeutics, Inc. | -19.67M |
| Black Diamond Therapeutics, Inc. | -8.338M |
| Invivyd, Inc. | -32.11M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -5.147M |
| Cash from Financing (Quarterly) | -0.023M |
| Free Cash Flow | -26.46M |
| Free Cash Flow Per Share (Quarterly) | -0.022 |
| Free Cash Flow to Equity (Quarterly) | -5.424M |
| Free Cash Flow to Firm (Quarterly) | -5.694M |
| Free Cash Flow Yield | -12.76% |